- Home
- RIGL
as 12-20-2024 4:00pm EST
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 486.4M | IPO Year: | 2000 |
| Target Price: | $34.80 | AVG Volume (30 days): | 203.8K |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.22 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.48 - $29.82 | Next Earning Date: | 11-07-2024 |
| Revenue: | $157,374,000 | Revenue Growth: | 21.65% |
| Revenue Growth (this year): | 48.98% | Revenue Growth (next year): | 14.43% |
Latest Rigel Pharmaceuticals Inc. News
RIGL Breaking Stock News: Dive into RIGL Ticker-Specific Updates for Smart Investing
Simply Wall St.
10 days ago
Recent 26% pullback isn't enough to hurt long-term Rigel Pharmaceuticals (NASDAQ:RIGL) shareholders, they're still up 50% over 1 year
MT Newswires
13 days ago
Rigel Pharmaceuticals Reports Initial Efficacy, Safety Data from Cancer Drug Study
PR Newswire
13 days ago
Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition
MT Newswires
16 days ago
B. Riley Adjusts Price Target on Rigel Pharmaceuticals to $27 From $17, Maintains Neutral Rating
MT Newswires
20 days ago
Rigel Pharmaceuticals Says its R289 Hematology Drug Candidate Receives Fast-Track Designation From US FDA
PR Newswire
20 days ago
Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS
Zacks
a month ago
How Much Upside is Left in Rigel (RIGL)? Wall Street Analysts Think 28.28%
Zacks
a month ago
Zacks.com featured highlights Rigel, Synchrony Financial, SkyWest, Allient and Rush Street Interactive
Compare RIGL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RIGL Rigel Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.